Fat contents (g/kg) in breast meat and liver. by Miloš Skřivan (5122037)

Subjects:

Forest plots illustrate the mean difference in; (A) hospital stay, (B) ICU stay, (C) intubation time; with subgroup analysis. by Mohamed R. Abdelraouf (21501468)

CaCl₂ and MnCl₂ treatment significantly reduced Pol I occupancy on the rDNA template. by Abigail K. Huffines (20721555)

“…If the <i>p</i>-value < 0.05, that was deemed a significant difference between the two treatment groups and was indicated with either a green (increased occupancy) or black (decreased occupancy) line below the histogram for the CaCl₂ treated samples with respect to the untreated samples. …”

Comparing detector performance against increasing signal to noise ratios. by Bernd Porr (32394)

Linear covariate analysis of prognostically significant metabolites. Presenting the effect sizes of metabolites that showed significant differences among prognostic groups in ICU-treated COVID-19 patients. Metabolites were included based on an F-value > 2.5 and a p-value < 0.05. Metabolites marked with a single asterisk (*) were significant in both two-way ANOVA and ASCA, whereas those marked with double asterisks (**) were significant only in two-way ANOVA. Positive effect sizes indicate an increase in metabolite concentration between the compared groups, while negative values indicate a decrease. by Emir Matpan (21655811)

“…Positive effect sizes indicate an increase in metabolite concentration between the compared groups, while negative values indicate a decrease.…”

The mean number of the emerged <i>D. melanogaster</i> adults. Mean number (±SE) of emerged adults and average percentage (±SE) of the residual fertility at the different treatment... by Flavia Cerasti (21655934)

A) RT-qPCR analysis of <i>Yap</i>, <i>Taz</i>, and <i>Tead2</i> shows a significant decrease in transcript levels over postnatal stages from P0 to P28. by Heather L. Dingwall (14573796)

Difference in by Akihiro Kakimoto (343218)

Subjects:

Experimental protocol. by Akihiro Kakimoto (343218)

Subjects:

Relationship between the change in by Akihiro Kakimoto (343218)

Subjects:

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects: